SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hochberg MC, Feldman D, Stevens MB, Arnett FC, Reichlin M. Antibody to Jo-1 in polymyositis/dermatomyositis: associations with interstitial pulmonary disease. J Rheumatol 1984; 11: 6635.
  • 2
    Targoff IN, Trieu EP, Plotz PH, Miller FW. Antibodies to glycyl–transfer RNA synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum 1992; 35: 82130.
  • 3
    Targoff IN, Arnett FC. Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase). Am J Med 1990; 88: 24151.
  • 4
    Marguerie C, Bunn CC, Beynon HC, Bernstein RM, Hughes JM, So AK, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes [review]. Q J Med 1990; 77: 101938.
  • 5
    Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70: 36074.
  • 6
    Bernstein RM, Morgan SH, Chapman J, Bunn CC, Mathews MB, Turner-Warwick M, et al. Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Br Med J (Clin Res Ed) 1984; 289: 1512.
  • 7
    Hirakata M, Suwa A, Nagai S, Kron M, Trieu EP, Mimori T, et al. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol 1999; 162: 231520.
  • 8
    Oddis CV, Medsger TA Jr, Cooperstein LA. A subluxing arthropathy associated with the anti–Jo-1 antibody in polymyositis/dermatomyositis. Arthritis Rheum 1990; 33: 16405.
  • 9
    Schnabel A, Reuter M, Biederer J, Richter C, Gross WL. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 2003; 32: 27384.
  • 10
    Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999; 353: 17623.
  • 11
    Kendall FP. Key to muscle grading: muscles: testing and function. Baltimore: Williams & Wilkins; 1993. p. 18892.
  • 12
    Bohan A, Peter J. Polymyositis and dermatomyositis. N Engl J Med 1975; 292: 3447.
  • 13
    Yamanishi Y, Maeda H, Konishi F, Hiyama K, Yamana S, Ishioka S, et al. Dermatomyositis associated with rapidly progressive fatal interstitial pneumonitis and pneumomediastinum. Scand J Rheumatol 1999; 28: 5861.
  • 14
    Clawson K, Oddis CV. Adult respiratory distress syndrome in polymyositis patients with the anti–Jo-1 antibody. Arthritis Rheum 1995; 35: 151923.
  • 15
    Ito M, Kaise S, Suzuki S, Kazuta Y, Sato Y, Miyata M, et al. Clinico-laboratory characteristics of patients with dermatomyositis accompanied by rapidly progressive interstitial lung disease. Clin Rheumatol 1999; 18: 4627.
  • 16
    Grau JM, Miro O, Pedrol E, Casademont J, Masanes F, Herrero C, et al. Interstitial lung disease related to dermatomyositis: comparative study with patients without lung involvement. J Rheumatol 1996; 23: 19216.
  • 17
    Yoshida T, Koga H, Saitoh F, Sakamoto M, Harada M, Yoshida H, et al. Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis. Intern Med 1999; 38: 7338.
  • 18
    Schnabel A, Reuter M, Gross WL. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 1998; 41: 121520.
  • 19
    Moolman JA, Bardin PG, Rossouw DJ, Joubert JR. Cyclosporin as a treatment for interstitial lung disease of unknown etiology. Thorax 1991; 46: 5925.
  • 20
    Maeda K, Kimura R, Komuta K, Igarashi T. Cyclosporin treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis. Scand J Rheumatol 1997:26: 249.
  • 21
    Nawata Y, Kurasawa K, Takabayashi K, Miike S, Watanabe N, Hiraguri M, et al. Corticosteroid resistant interstitial pneumonitis in polymyositis/dermatomyositis: prediction and treatment with cyclosporin A. J Rheumatol 1999; 26: 152733.
  • 22
    Kobayashi K, Yamada M, Takahashi Y, Kawamura N, Okano M, Sakiyama Y, et al. Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporin A. Rheumatology (Oxford) 2003; 42: 3714.
  • 23
    Kurasawa K, Nawata Y, Takabayashi K, Kumano K, Kita Y, Takiguchi Y, et al. Activation of pulmonary T cells in corticosteroid-resistant and -sensitive interstitial pneumonitis in dermatomyositis/polymyositis. Clin Exp Immunol 2002; 129: 5418.
  • 24
    Plosker G, Foster R. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000; 59: 32389.
  • 25
    Van Gelder T. Drug interactions with tacrolimus. Drug Saf 2002; 25: 70712.
  • 26
    Christians U, Jacobsen W, Benet L, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus [review]. Clin Pharmacokinet 2002; 41: 81351.
  • 27
    Tanaka H, Kuroda A, Marusawa H, Hashimoto M, Hatanaka H, Kino T, et al. Physicochemical properties of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 1987; 19 Suppl 6:116.
  • 28
    Kino T, Katanaka K, Hashimoto H, Nishiyama M, Goto T, Okuhara M, et al. FK-506, a novel immunosuppressant isolated from Streptomyces. I. Fermentation, isolation, and physico-chemical and biologic characteristics. J Antibiot (Tokyo) 1987; 40: 124955.
  • 29
    Thomson A, Carroll P, McCauley J, Woo J, Abu-Elmagd K, Starzl TE, et al. FK 506: a novel immunosuppressant for treatment of autoimmune disease: rationale and preliminary clinical experience at the University of Pittsburgh [review]. Springer Semin Immunopathol 1993; 14: 32344.
  • 30
    Kainz A, Harabacz I, Cowlrick I, Gadgil S, Hagiwara D. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation 2000; 70: 171821.
  • 31
    Kruszka SJ, Gherman RB. Successful pregnancy outcome in a lung transplant recipient with tacrolimus immunosuppression: a case report. J Reprod Med 2002; 47: 602.
  • 32
    Friedman A, Targoff I, Arnett F. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 1996; 26: 45967.
  • 33
    Xaubet A, Agusti C, Luburich P, Roca J, Monton C, Ayuso MC, et al. Pulmonary function tests and CT scan in the management of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158: 4316.
  • 34
    Flaherty K, Martinez F. The role of pulmonary function testing in pulmonary fibrosis. Curr Opin Pulm Med 2000; 6: 40410.